相似文献
1
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.
Nanomedicine (Lond). 2015 Feb;10(3):447-63. doi: 10.2217/nnm.14.179.
2
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.
Expert Opin Drug Metab Toxicol. 2015;11(9):1419-33. doi: 10.1517/17425255.2015.1057496. Epub 2015 Jul 20.
3
Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.
Methods Mol Biol. 2018;1831:201-228. doi: 10.1007/978-1-4939-8661-3_15.
4
Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.
Nanomedicine (Lond). 2017 Aug;12(16):2021-2042. doi: 10.2217/nnm-2017-0101. Epub 2017 Jul 26.
5
Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.
Clin Pharmacol Ther. 2012 May;91(5):802-12. doi: 10.1038/clpt.2012.12.
6
Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.
Nanomedicine (Lond). 2017 Oct;12(20):2519-2532. doi: 10.2217/nnm-2016-0421. Epub 2017 Sep 27.
7
Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27.
8
Bankruptcy filing worries developers of nanoparticle cancer drugs.
Nature. 2016 May 19;533(7603):304-5. doi: 10.1038/533304a.
9
Concept and clinical evaluation of carrier-mediated anticancer agents.
Oncologist. 2008 Mar;13(3):248-60. doi: 10.1634/theoncologist.2007-0180.
10
Nanoparticles generated by PEG-Chrysin conjugates for efficient anticancer drug delivery.
Eur J Pharm Biopharm. 2014 Aug;87(3):454-60. doi: 10.1016/j.ejpb.2014.03.011. Epub 2014 Mar 29.
引用本文的文献
1
Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1.
ACS Appl Mater Interfaces. 2025 Jan 8;17(1):363-373. doi: 10.1021/acsami.4c15472. Epub 2024 Dec 17.
2
Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer's Disease Management.
Pharmaceutics. 2023 Dec 29;16(1):58. doi: 10.3390/pharmaceutics16010058.
3
Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer.
Int J Nanomedicine. 2023 Oct 11;18:5713-5732. doi: 10.2147/IJN.S424932. eCollection 2023.
4
Genetically engineered cellular nanoparticles for biomedical applications.
Biomaterials. 2023 May;296:122065. doi: 10.1016/j.biomaterials.2023.122065. Epub 2023 Feb 20.
5
Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy.
Pharmaceutics. 2022 Jun 27;14(7):1362. doi: 10.3390/pharmaceutics14071362.
6
DNA-Liposome Hybrid Carriers for Triggered Cargo Release.
ACS Appl Bio Mater. 2022 Aug 15;5(8):3713-3721. doi: 10.1021/acsabm.2c00225. Epub 2022 Jul 15.
7
Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.
Int J Mol Sci. 2022 May 16;23(10):5536. doi: 10.3390/ijms23105536.
8
Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection.
RSC Adv. 2018 Mar 14;8(19):10425-10436. doi: 10.1039/c8ra00154e. eCollection 2018 Mar 13.
9
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Adv Drug Deliv Rev. 2022 Mar;182:114116. doi: 10.1016/j.addr.2022.114116. Epub 2022 Jan 24.
10
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model.
Ther Adv Med Oncol. 2021 Oct 29;13:17588359211053700. doi: 10.1177/17588359211053700. eCollection 2021.
本文引用的文献
1
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old.
Cancer Chemother Pharmacol. 2014 Mar;73(3):517-24. doi: 10.1007/s00280-014-2378-z. Epub 2014 Jan 18.
2
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
PLoS One. 2014 Jan 8;9(1):e82331. doi: 10.1371/journal.pone.0082331. eCollection 2014.
3
Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.
Sci Transl Med. 2013 Oct 30;5(209):209ra152. doi: 10.1126/scitranslmed.3006839.
4
Combining two strategies to improve perfusion and drug delivery in solid tumors.
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18632-7. doi: 10.1073/pnas.1318415110. Epub 2013 Oct 28.
5
Strategies for advancing cancer nanomedicine.
Nat Mater. 2013 Nov;12(11):958-62. doi: 10.1038/nmat3792.
6
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.
J Pharmacol Exp Ther. 2013 Dec;347(3):599-606. doi: 10.1124/jpet.113.208801. Epub 2013 Sep 16.
7
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy.
Biomaterials. 2013 Nov;34(33):8424-9. doi: 10.1016/j.biomaterials.2013.07.038. Epub 2013 Jul 27.
8
Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.
Nanomedicine. 2014 Jan;10(1):109-17. doi: 10.1016/j.nano.2013.07.005. Epub 2013 Jul 24.
9
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.
PLoS One. 2013 May 1;8(5):e61359. doi: 10.1371/journal.pone.0061359. Print 2013.
10
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
Cancer Res. 2013 Apr 15;73(8):2412-7. doi: 10.1158/0008-5472.CAN-12-4561. Epub 2013 Feb 19.
Zotero 插件